Y
Yanwei Zhang
Researcher at Shanghai Jiao Tong University
Publications - 76
Citations - 1060
Yanwei Zhang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 14, co-authored 56 publications receiving 592 citations.
Papers
More filters
Journal ArticleDOI
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Tianqing Chu,Runbo Zhong,Hua Zhong,Bo Zhang,Wei Zhang,Chunlei Shi,Jialin Qian,Yanwei Zhang,Qing Chang,Xueyan Zhang,Yu Dong,Jiajun Teng,Zhiqiang Gao,Huiping Qiang,Wei Nie,Yiming Zhao,Yuchen Han,Ya Chen,Baohui Han +18 more
TL;DR: In this article, the efficacy and safety of sintilimab combined with anlotinib as first-line therapy for advanced NSCLC from a phase 1b trial (NCT03628521) were evaluated.
Journal ArticleDOI
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive Egfr mutations: A randomized controlled trial
Baohui Han,Bo Jin,Tianqing Chu,Yanjie Niu,Yu Dong,Jianlin Xu,A. Gu,Hua Zhong,Huimin Wang,Xueyan Zhang,Chunlei Shi,Yanwei Zhang,Wei Zhang,Yuqing Lou,Lei Zhu,Jun Pei +15 more
TL;DR: It is suggested that treatment with pemetrexed plus carboplatin combined with gefitinib could provide better survival benefits for patients with lung adenocarcinoma harboring sensitive EGFR mutations.
Journal ArticleDOI
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Jianlin Xu,Bo Jin,Tianqing Chu,Xue Dong,Haitang Yang,Yanwei Zhang,Dan Wu,Yuqing Lou,Xueyan Zhang,H. Wang,Baohui Han +10 more
TL;DR: These results suggest that EGFR TKI therapy is effective in patients with L861Q/G719X/Del-19+L858R/del-19 or L858-R+other mutations; less effective in Patients with 20ins/Del, 19 or L 858R+T790M.
Journal ArticleDOI
Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
Wenjia Yang,Fangfei Qian,Jiajun Teng,Huimin Wang,Christian Manegold,Lothar R. Pilz,Weiland Voigt,Yanwei Zhang,Jianding Ye,Qunhui Chen,Baohui Han +10 more
TL;DR: Compared to usual care, LDCT led to a 74.1% increase in detecting early-stage lung cancer in the high-risk population of China with both smoking and non-smoking related factors.
Journal ArticleDOI
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Jun Lu,Hua Zhong,Tianqing Chu,Xueyan Zhang,Rong Li,Jiayuan Sun,Runbo Zhong,Yuqin Yang,Mohammad Shah Alam,Yuqing Lou,Jianlin Xu,Yanwei Zhang,Jun Wu,Xiaowei Li,Xiaodong Zhao,Kai Li,Liming Lu,Baohui Han +17 more
TL;DR: A novel anti-angiogenesis mechanism of anlotinib via inhibiting CCL2 in an NCI-H1975-derived xenograft model is reported and changes in serum CCL1 levels are suggested to be used to monitor and predict clinical outcomes in anlot inib-administered refractory advanced NSCLC patients using third-line therapy or beyond.